The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

The goal of this clinical trial is to test the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutation on codon 12/13 mutation who has multiple myeloma or high-risk smoldering multiple myeloma. The main question it aims to answer are: Is TG01/QS-21 vaccination safe and tolerable for this patient group? Is TG01/QS-21 vaccination treatment efficient in this group in terms of increased overall response rate, overall survival rate, progression-free survival, and time til next treatment? Is there an immunological response to the vaccine? Participants will be g

Trial Details

NCT ID
NCT05841550
Phase
PHASE1 / PHASE2
Sponsor
Oslo University Hospital
Status
RECRUITING
Cancer Type
Smoldering Myeloma Multiple Myeloma
Interventions
  • TG01
Locations (sample)
  • Oslo, Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

  • Male or female patients ≥ 18 years of age
  • RAS mutation (KRAS/NRAS codon 12/13 mutation) detected on archival or fresh bone marrow material with VariantPlex Myeloid Panel
  • Confirmed diagnosis of high-risk smoldering multiple myeloma (SMM) according to IMWG criteria (30) and high-risk criteria as listed up below OR con…
  • 1 line of treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Smoldering Myeloma Multiple Myeloma Trials on Trialify →